Human Copper-Containing Amine Oxidases in Drug Design and Development

Serhii Vakal 1, Sirpa Jalkanen 2, Käthe M. Dahlström 1 and Tiina A. Salminen 1,*†

1 Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, FI-20520 Turku, Finland; serhii.vakal@abo.fi (S.V.); Kathe.Dahlstrom@abo.fi (K.M.D.)
2 MediCity Research Laboratory, University of Turku, Tykistökatu 6A, FI-20520 Turku, Finland; sirpa.jalkanen@utu.fi
* Correspondence: tiina.salminen@abo.fi; Tel.: +358-40-515-1201

Abstract: Two members of the copper-containing amine oxidase family are physiologically important proteins: (1) Diamine oxidase (hDAO; AOC1) with a preference for diamines is involved in degradation of histamine and (2) Vascular adhesion protein-1 (hVAP-1; AOC3) with a preference for monoamines is a multifunctional cell-surface receptor and an enzyme. hVAP-1-targeted inhibitors are designed to treat inflammatory diseases and cancer, whereas the off-target binding of the designed inhibitors to hDAO might result in adverse drug reactions. The X-ray structures for both human enzymes are solved and provide the basis for computer-aided inhibitor design, which has been reported by several research groups. Although the putative off-target effect of hDAO is less studied, computational methods could be easily utilized to avoid the binding of VAP-1-targeted inhibitors to hDAO. The choice of the model organism for preclinical testing of hVAP-1 inhibitors is not either trivial due to species-specific binding properties of designed inhibitors and different repertoire of copper-containing amine oxidase family members in mammalian species. Thus, the facts that should be considered in hVAP-1-targeted inhibitor design are discussed in light of the applied structural bioinformatics and structural biology approaches.

Keywords: copper-containing amine oxidases; vascular adhesion protein-1; diamine oxidase; inhibitor design; protein-inhibitor interactions; computer-aided drug design

1. Introduction

In humans, the copper-containing amine oxidase (CAO) family consists of three proteins [1]. Diamine oxidase (hDAO; AOC1) prefers diamines and is involved in the degradation of histamine [2], while retina-specific amine oxidase (hRAO; AOC2) is a monoamine oxidase with enzymatic activity in retina [3], and vascular adhesion protein-1 (hVAP-1; AOC3) is a multifunctional cell-surface receptor and an enzyme with preference for monoamines [4]. Both hDAO and hVAP-1 are physiologically essential proteins, but little is known about the physiological function of hRAO. In the CAO-catalyzed reaction, primary amines are converted to the corresponding aldehydes accompanied by the production of hydrogen peroxide and ammonia (for a review, see [5]). The structural characterization of human CAOs has revealed a dimeric protein with a deeply buried active site characterized by highly conserved residues and several common features involved in the catalytic reaction, including a topaquinone (TPQ) cofactor and a conserved aspartate residue, as well as three conserved histidine residues that bind the copper ion crucial for the TPQ biogenesis (hVAP-1: [6–10]; hDAO: [11–13] (Figure 1A,B). Three arms that protrude from one monomer to the other one stabilize the tight dimer of human CAOs, where each monomer consists of three domains, namely, D2, D3, and D4 (Figure 1A). The D4 forms...
the deeply buried catalytic site, and Arm I of monomer B (pink) contributes to ligand binding into monomer A (cyan) (Figure 1B).

![Figure 1](image-url)

**Figure 1.** Structural features of human copper-containing amine oxidase (CAO) dimer. (A) Side view of the hVAP-1 dimer (PDB code 4BTY). Three long β-hairpin arms stabilize the tight dimer; (B) top view of hVAP-1 shows the D2, D3, and D4 domains in each monomer. In the deeply buried active site, the copper ion (orange sphere) is coordinated by the three conserved histidine residues (H520, H522, and H684 in hVAP-1). TPQ (TPQ471) is shown in off-copper, productive conformation, and the catalytic aspartate (Asp386) resides next to the quinone cofactor. Arm I (pink) extending from D4 of monomer B (pink) forms one wall of the active site channel. The black arrow depicts the direction from the catalytic site via the active site channel formed by the D3 and D4 domains to the surface of the protein.

In addition to its enzymatic activity, hVAP-1 is an adhesion protein involved in leukocyte trafficking, whose roles in leukocyte adhesion and inflammatory conditions are well characterized (for review see [14–17]). In adhesion, Sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9), a leukocyte surface receptor [18], forms multivalent interactions with hVAP-1 on the endothelial cell surface [19]. Typically, healthy humans have a low level of hVAP-1 activity, but the levels are elevated upon inflammation when hVAP-1 is translocated onto the luminal surface of the endothelium [20–22]. Therefore, molecules that bind to hVAP-1 can be used as tracers in positron emission tomography (PET) to detect the site of inflammation in vivo [18]. Additionally, the anti-inflammatory potential of VAP-1 inhibitors is shown in several inflammation models (reviewed in [17]), which have proven that the enzymatic activity of hVAP-1 is crucial for leukocyte adhesion and especially required for the hVAP-1-dependent extravasation in vivo [23]. Moreover, anti-hVAP-1 antibodies, which do not affect the enzymatic activity of hVAP-1, independently inhibit hVAP-1-mediated adhesion. Thus, both antibodies and small molecular inhibitors could be used as anti-inflammatory drugs to treat acute and
chronic inflammatory conditions. There is also substantial evidence that hVAP-1 inhibitors could be utilized in preventing tumor progression and metastatic spread of cancer (reviewed in [14,17]).

hDAO is the main enzyme in the extracellular degradation of histamine [24]. It is expressed in the kidney, placenta, intestine, thymus, and seminal vesicles [25], and its functions are related to cell proliferation, inflammation, allergic response, and ischemia [11]. Decreased hDAO levels have been linked to histamine intolerance [26], and a decreased hDAO activity coupled to a high presence of histamine increases the probability for anaphylactic shock-like symptoms [27]. Normally, the plasma concentration of hDAO is elevated during pregnancy, and low levels of hDAO increase the risk of premature termination [28]. It is known that some pharmaceuticals, which are not targeted towards hDAO, inhibit its normal function (off-target effect) and thus cause harmful side effects (adverse drug reactions; ADRs) [11,27]. Consequently, it is a crucial drug safety issue to identify substances, which potently inhibit hDAO activity, to avoid their usage in the treatment of patients with hDAO deficiencies and conditions like varieties of urticaria, asthma, atopic dermatitis, mastocytosis, mastcell activation syndromes, and likely, pregnant women.

This review concentrates on the structural chemistry of hVAP-1 inhibitors whose binding site has been either predicted by computational studies or deciphered by X-ray crystallography. The current knowledge of the off-target effect of hDAO inhibition is also summarized and discussed in light of the hVAP-1-targeted inhibitor design. Furthermore, we highlight important facts and considerations that need to be taken into account in the hVAP-1 inhibitor design process to obtain potent and selective drug molecules.

2. Catalytic Mechanism of Copper Amine Oxidases

VAP-1 is a primary amine oxidase and, thus, catalyzes the oxidative deamination of primary amines, both exogenous (allylamine, benzylamine) and endogenous (methylamine and aminocetone). According to modern concepts [29–31], the reaction proceeds through a ping-pong mechanism. In the reductive half-reaction, TPQ is reduced by the substrate to generate the aldehyde product (Figure 2A); then, in the oxidative half-reaction, the reduced TPQ is reoxidized by molecular oxygen, which is accompanied by a release of hydrogen peroxide and ammonia [4,32] (Figure 2B). The overall reaction balance can be written as R-CH$_2$-NH$_3^+$ + H$_2$O + O$_2$ → R-COH + H$_2$O$_2$ + NH$_4^+$.

The reductive half-reaction comprises three steps (Figure 2A); first, the oxidized TPQ reacts with a protonated primary amine to form a so-called “substrate Schiff base” (quinone imine), and then, this adduct is converted to a “product Schiff base” (quinolaldimine), which is facilitated by a conserved Asp-386 catalyzing proton abstraction [33]. In the final step, the aldehyde product (R-COH) is hydrolytically released generating the reduced TPQ (aminoquinol).

TPQ coordinates the Cu(II) ions; two states named “off”-copper and “on”-copper have been characterized and shown to exist in equilibrium in solution [34]. In the “off”-copper conformation, oxidized TPQ does not interact with Cu(II), which is coordinated by three histidine residues and two water molecules, while in the “on”-copper state, the waters are displaced, and TPQ interacts with the copper.

The oxidative half-reaction proceeds through four steps via one of two possible ways (Figure 2B). In both scenarios, the intermediate molecules are the same, but the electron transfer pathway differs. Currently, it is not clear whether molecular oxygen reacts directly with reduced TPQ, TPQ semiquinone, or Cu(I) [31] as there is evidence for each option. In the first scenario, oxygen interacts with Cu(I) bound to TPQ-semiquinone and then is reduced to a reactive O$_2$•− via inner-sphere electron transfer (Figure 2B, upper scheme) [35]. Alternatively, according to Mure et al. [36], oxygen binds to hydrophobic residues near the reduced TPQ, which reduces O$_2$ to O$_2$•− via outer-sphere electron transfer. Then, in both scenarios, Cu(II)-hydroperoxide and TPQ-iminoquinone are generated [37]. At the final step, iminoquinone is hydrolyzed, and ammonia is released with the concomitant production of hydrogen peroxide and oxidized TPQ-Cu(II) regeneration.
Recent kinetic and computational studies suggest that a redox-active metal in copper amine oxidases is needed to catalyze the reduction of O$_2$ to H$_2$O$_2$ [38]. Cu(I) reacts with O$_2$ by inner-sphere electron transfer to eliminate charge accumulation due to O$_2^+$, thus lowering the free energy barrier by minimizing the outer-sphere reorganization energy [39]. Copper also facilitates long-range proton-coupled electron transfer to bind oxygen via the H-bond network [38]. However, it should be noted that most of the data on catalytic details have been acquired using non-mammalian bacterial, plant, and fungal amine oxidases, primarily Escherichia coli, Arthrobacter globiformis, and Hansenula polymorpha orthologs.

![Proposed AOC catalytic mechanism](image)

**Figure 2.** Proposed AOC catalytic mechanism. (A) Mechanism of reductive half-reaction; (B) two proposed mechanisms of oxidative half-reaction; inner-sphere electron transfer pathway is shown above, while the outer-sphere is below. Protein represented as a blue rectangle. Based on the schemes presented in [31].

3. Medical Relevance of Targeting hVAP-1

3.1. Basis for Clinical Targeting of VAP-1

Due to the multifunctional nature of VAP-1 and its involvement in inflammation via adhesive leukocyte–endothelial cell interactions and production of end-products, which modulate other adhesion and signaling molecules triggering inflammation, VAP-1 inhibition provides us with a novel approach to overcome several diseases having inflammatory components. Moreover, the enzymatic activity of VAP-1 modifies its substrate to an aldehyde that is able to promote the formation of advanced glycation end-products damaging vasculature, for example, in diabetes. Indeed, a multitude of preclinical studies using mice, rats, and rabbits have shown beneficial effects of targeting VAP-1 in several disease models. They include autoimmune and other inflammations, viral and bacterial infections, ischemia-reperfusion injuries, fibrosis, cancer, and metabolic diseases (reviewed in [17]). These studies, together with the findings that hVAP-1 is translocated to the endothelial cell surface from intracellular storage granules at sites of inflammation and that increased concentrations of hVAP-1 are found in several diseases, form the basis for clinical targeting of VAP-1 (reviewed in [17]). Moreover, easy accessibility of VAP-1 on inflamed endothelium for potential imaging agents makes VAP-1 an optimal target to search for inflammatory foci that is often challenging in clinics.
3.2. Clinical Trials

After the discovery of leukocyte ligands for VAP-1 [18,40], a VAP-1 binding peptide of Siglec-9 has been developed as a novel imaging agent. This peptide binds to VAP-1-positive vessels in rheumatoid synovium [41], and the peptide conjugated with ⁶⁸Ga-Dota has just recently successfully passed the phase I clinical trial [42]. It is going to further clinical trials meant to test this peptide as a diagnostic and follow-up tool for arthritic lesions in PET imaging.

Several companies are also developing therapeutics to block the function of hVAP-1. They include both antibodies and small molecular inhibitors (Table 1). Currently, active clinical trials or completed trials with accessible information about their outcome are discussed below. BioTie Therapies (currently Acorda) developed a fully human anti-hVAP-1 antibody Timolumab (BTT1023). It has been well-tolerated and shown efficacy both in early clinical trials for rheumatoid arthritis and psoriasis. In contrast, a phase 2 proof-of-concept trial for 19 patients suffering from primary sclerosing cholangitis did not meet the pre-defined efficacy criteria in the interim analysis, and the trial was terminated [43].

Astellas’ ASP8232 VAP-1 inhibitor was tested in placebo-controlled phase II trials for diabetic macular edema and diabetic nephropathy [44,45]. In macular edema, this inhibitor was not effective, although it efficiently inhibited VAP-1 enzymatic activity in plasma. How well the orally administered inhibitor reached the vitreous fluid was not tested and the authors speculate that the route of delivery should be reassessed in the future trials. In contrast, 12-week daily treatment with orally administered ASP8232 significantly reduced albuminuria of diabetic patients. The results of this trial suggest that diabetic kidney disease can be delayed by inhibiting VAP-1 activity. In both of these trials, ASP8232 was safe and well-tolerated.

Pharmaxis developed BXS4728A to inhibit VAP-1 activity and performed a phase I clinical trial. Moreover, this compound turned out to be safe and well-tolerated. It is orally bioavailable and has long-lasting inhibitory effects. Boehringer-Ingelheim acquired this compound and tested it in a phase II trial for non-alcoholic steatohepatitis (NASH) that is a growing health problem connected to obesity and type 2 diabetes and can result in permanent liver damage. The study met its pre-specified endpoints including a decrease in NASH biomarkers but due to potentially harmful interactions with a drug (not defined in the press release) used by NASH patients, the company will not continue to develop the inhibitor to this group of patients. However, they continue to run phase II trials for diabetic retinopathy, but in this multi-center double-blind study involving 100 patients with moderately severe non-proliferative diabetic retinopathy, the diabetic macular edema is not targeted [46]. Currently, also Terns Pharmaceuticals runs phase I trial for NASH with its VAP-1 inhibitor, TERN-201 (https://www.ternspharma.com/pipeline). Besides these, several other companies have VAP-1-targeted programs in their pipeline for pulmonary diseases, pain, uveitis, multiple sclerosis, inflammatory bowel diseases, Alzheimer’s disease, and Parkinson’s disease at preclinical or inactive state. Which one of these will end up in clinical trials remains to be seen.

| Name and Structure | Type of Inhibition | Company | Current Status Ref. |
|-------------------|-------------------|---------|---------------------|
| Hydralazine | Mechanism-based | Novartis International AG, Switzerland | FDA Approved in 15.01.1953 for the treatment of hypertension; later discontinued due to the development of newer medications. [47,48] |
| LJP1207 | Mechanism-based | La Jolla Pharmaceutical Company, USA | Discontinued; not appropriate for drug development due to its potentially toxic allylhydrazine structure [49–53] |
| Name and Structure       | Type of Inhibition | Company                                      | Current Status                                                                 | Ref.       |
|-------------------------|--------------------|----------------------------------------------|--------------------------------------------------------------------------------|------------|
| ASP8232                 | Unknown            | R Tech Ueno Ltd., Japan; Astellas Pharma Europe BV, The Netherlands | Discontinued on Phase 2 trials (NCT02302079, NCT02218099) due to strategic prioritization | [44,45]   |
| PXS-4159A (R10)         | Mechanism-based    | Pharmaxis Ltd., Australia                    | In preclinical toxicology evaluation                                           | [54]       |
| PXS 4728A (BI 1467335)  | Mechanism-based    | Pharmaxis Ltd., Australia                    | Completed Phase II clinical trials for the treatment of non-alcoholic steatohepatitis (NCT01366735) | [55–57]   |
| PXS-4681A               | Mechanism-based    | Pharmaxis Ltd., Australia                    | Discontinued                                                                  | [58,59]   |
| LJP1586                 | Mechanism-based    | La Jolla Pharmaceutical Company, USA          | Discontinued                                                                  | [22,60–64]|
| TERN-201                | Mechanism-based    | Eli Lilly and Company; Terns Pharmaceuticals | Phase I clinical trials for the treatment of non-alcoholic steatohepatitis     | [65]       |
| PRX167700               | Unknown            | Cambridge Biotechnology, UK; Proximagen, UK; Roche, Switzerland | Completed Phase II clinical trials for the treatment of osteoarthritis (NCT01945346) |            |
| SzV-1287                | Mechanism-based    | Semmelweis University, Hungary               | In preclinical studies; patented as a mean to treat hyperalgesia and allodynia in traumatic neuropathy or neurogenic inflammation | [66–69]   |
| U-V002 (R7)             | Mechanism-based    | R Tech Ueno Ltd., Japan;                     | Unknown                                                                       | [70–73]   |
| BTT-2027                | Mechanism-based    | Biotie Therapies Corp.                       | Discontinued                                                                  | [20]       |
| BTT2052                 | Mechanism-based    | Biotie Therapies Corp.                       | Discontinued                                                                  | [74]       |
4. Structural Biology and Computer-Aided Drug Design in hVAP-1-Targeted Inhibitor Design

As hVAP-1 is a suitable drug design target, several potential hVAP-1 inhibitors have been published including hydrazines, thiazoles, benzamides, oxime-based inhibitors, aminoglycoside antibiotics, vitamin B1 derivatives, and peptides (Reviewed, e.g., in [32,75,76]). Nevertheless, most of the current hVAP-1 inhibitors are mechanism-based and bind irreversibly to the TPQ cofactor in a similar way as 2-hydrazinopyridine (2HP; PDB code 2C11) [7] (Figure 3). The irreversible binding mode is an undesirable feature for human drugs, since only new protein synthesis restores the function [77]. Thus, the design of reversible inhibitors specific for hVAP-1 would be highly beneficial. So far, pyridazinones (Figure 3; PDB codes 4BTY, 4BTX, and 4BTW; [10]), to our knowledge, are the only published inhibitors designed to have a reversible binding mode to hVAP-1. Figure 3 simultaneously shows both mechanism-based and reversible binding sites and modes via the overlaid 2HP and pyridazinone complex structures. It serves as a binding-site map for further discussion on the binding pose of the reviewed inhibitors for which the structural data is not publicly available (Tables 1 and 2).

Computer-aided drug design has been reported for several mechanism-based inhibitors (Table 2), and the results have provided foundations for some of the inhibitors that have entered clinical trials and/or have been extensively used in preclinical studies (Table 1).

![Figure 3](image_url)

**Figure 3.** Binding site map for the reviewed hVAP-1 inhibitors. The binding mode of mechanism-based inhibitors is depicted using the 2HP–hVAP-1 complex (PDB code 2C11; (A) mechanism-based; boxed in blue) as a representative structure and the binding mode of reversible inhibitors is illustrated using the overlaid pyridazinone–hVAP-1 complex (PDB code 4BTY; (B) reversible; boxed in red). Circled numbering 1–7 with color-coding pinpoint the common interaction sites in the catalytic site (blue box) and the active site channel (red box) of hVAP-1. The same coding scheme is used in Table 2.
Table 2. List of computational studies modeling the interactions between various inhibitors and hVAP-1.

| Inhibitor         | Type of Inhibitor, IC50 | Used VAP-1 Structure | Docking Tool | Ref. |
|-------------------|-------------------------|----------------------|--------------|------|
| **Hydrazine Alcohols** |                         |                      |              |      |
| R1: Compound 2a,b | Mechanism-based, 0.04–0.15 μM | 2C11 | GOLD 3.1.1 | [78] |
| R2: Compound 8    | Mechanism-based, 1.2 μM | 2C11 | GOLD 3.1.1 | [78] |
| R3: Compound 12   | Mechanism-based, 0.26 μM | 2C11 | GOLD 3.1.1 | [78] |
| R4: Compound 11a–d| Mechanism-based, 0.28–1.18 μM | 2C11 | GOLD 3.1.1 | [78] |
| **Thiazoles**      |                         |                      |              |      |
| R5: Compound 10   | Mechanism-based, 0.23 μM | 2C11 | GOLD 5.0 | [79] |
| R6: Compound 35a  | Mechanism-based, 34 nM | 2C11 | GOLD 5.0 | [80] |
### Interacting residues: Covalent bond between guanidine group and TPQ; π–proton interactions of sulfonyl moiety with L447, amide nitrogen with Y176, and guanidine nitrogen with Y384.

**R7: Compound 35c**

![Chemical Structure of Compound 35c](image)

Mechanism-based, 20 nM 2C11 GOLD 5.0 [80]

**Indanols**

**BTT2052**

Mechanism-based, 0.06 µM 1US1 Manual docking [74]

**1H-imidazol-2-amines**

**R8: Compound 19**

![Chemical Structure of Compound 19](image)

Mechanism-based, 32 µM 2C11 GOLD 5.1 [81]

**R9: Compound 37b**

![Chemical Structure of Compound 37b](image)

Mechanism-based, 19 nM 2C11 GOLD 5.1 [81]

**Allylamines**

**R10: Compound 28**

![Chemical Structure of Compound 28](image)

Mechanism-based, 10 nM ? MOE 2011.10 [54]

**Interacting residues: Covalent bond between the amine group and TPQ; π–π interaction between imidazole ring and Y384; π–proton interaction of benzene ring with L469.**

---

**Table 2. Cont.**

| Inhibitor | Type of Inhibitor, IC₅₀ | Used VAP-1 | Docking Tool | Ref. |
|-----------|-------------------------|------------|--------------|------|
| Compound 35c | - | - | - | - |
| Compound 19 | - | - | - | - |
| Compound 37b | - | - | - | - |
| Compound 28 | - | - | - | - |
Table 2. Cont.

| Inhibitor | Type of Inhibitor, IC₅₀ | Used VAP-1 Structure | Docking Tool | Ref. |
|-----------|-------------------------|----------------------|--------------|------|
| Phenyl-piperidinyl amine | | | | |
| R11: ELP12 | | | | |
| R12: Compound 4a | | | | |
| R13: Compound 4g | | | | |
| R14: Compound 17h | | | | |

**Interacting residues:** Salt bridges between amino groups of R11 with the carboxylates of D180 and D446 and H-bonds with the side-chain of Y448 and with the backbone carbonyl of T424; an aromatic ring is stacked to the ring of Y176; hydrophobic interactions with F173, Y394, P397, I425, and L447; H-bond with Y394.

**Glycine amides**

| Inhibitor | Type of Inhibitor, IC₅₀ | Used VAP-1 Structure | Docking Tool | Ref. |
|-----------|-------------------------|----------------------|--------------|------|
| R12: Compound 4a | | | | |
| R13: Compound 4g | | | | |
| R14: Compound 17h | | | | |

**Interacting residues:** Covalent bond between the primary amine group and TPQ; CH–p interaction with L447, CH–O interaction with the L468 backbone carbonyl oxygen, arene–H interaction with L447.

**4.1. X-Ray Structures of hVAP-1 Complexes for Docking Studies and Inspiration for Drug Design**

Most of the docking studies (Table 2, Table S1) have been conducted using the 2-hydrazinopyridine (2HP) complex of hVAP-1 as the target protein (PDB code 2C11) [7] and, thus, the focus is on the special features of this structure and its comparison to other solved structures. Moreover, the crystal structures of hVAP-1 in complex with imidazole (PDB codes 2Y73 and 2Y74 [9]) are presented as
they unintentionally have provided valuable data on the inhibitor binding properties of hVAP-1. All publicly available X-ray structures of hVAP-1 and hDAO are listed in Table 3.

Table 3. A comprehensive list of experimentally solved structures of hVAP-1 and diamine oxidase (DAO) deposited into the Protein Data Bank as of 15 January 2020.

| PDB ID | Resolution, Å | Expression System | Date Deposited | Ligands | Inhibition Type, IC50/Ki | Ref. |
|--------|---------------|-------------------|----------------|---------|-------------------------|------|
| 1PU4   | 2.90          | Cricetulus griseus (CHO cells) | 24.06.03       | —       | n.a.1                   | [8]  |
| 1US1   | 2.90          | Cricetulus griseus (CHO cells) | 17.11.03       | —       | n.a.                    | [8]  |
| 2C10   | 2.50          | Homo sapiens (HEK293 cells) | 09.09.05       | —       | n.a.                    | [7]  |
| 2C11   | 2.90          | H. sapiens (HEK293 cells) | 09.09.05       | 2-Hydrizinopyridine | Mechanism-based, n.d.² | [7]  |
| 2Y73   | 2.60          | H. sapiens (human serum) | 28.01.11       | Imidazole | Mechanism-based, n.d.² | [9]  |
| 2Y74   | 2.95          | H. sapiens (human serum) | 28.01.11       | Imidazole | Mechanism-based, n.d.² | [9]  |
| 3ALA   | 2.90          | Cricetulus griseus (CHO cells) | 29.07.10       | —       | n.a.                    | [85] |

**R15:** 5-(cyclohexylamino)-2-phenyl-6-(1H-1,2,4-triazol-5-yl)-3(2H)-pyridazinone

Reversible IC50 = 71 nM

**R16:** 5-isopropylamino-2-phenyl-6-(1H-1,2,4-triazol-5-yl)-3(2H)-pyridazinone

Reversible IC50 = 290 nM

**R17:** 5-[4-(4-methylpiperazin-1-yl)phenylamino]-2-(4-chlorophenyl)-6-(1H-1,2,4-triazol-5-yl)-3(2H)-pyridazinone

Reversible IC50 = 20 nM
Table 3. Cont.

| PDB ID | Resolution, Å | Expression System | Date Deposited | Ligands | Inhibition Type, IC50/Ki | Ref. |
|--------|----------------|-------------------|----------------|---------|--------------------------|-----|
| 3HI7   | 1.80           | Drosophila melanogaster (S2 cells) | 19.05.09 | —       | n.a.                     | [11]|
| 3HIG   | 2.09           | Drosophila melanogaster (S2 cells) | 19.05.09 | Berenil (4-[2(E)-3-(4-carbamimidoylphenyl)triaz-2-en-1-yl]benzene-1-carboximidamide) | ReversibleKi = 13 nM | [11]|
| 3HII   | 2.15           | Drosophila melanogaster (S2 cells) | 20.05.09 | Pentamidine (1,5-bis(4-aminophenoxy)pentane) | ReversibleKi = 290 nM | [11]|
| 3KST   | 2.11           | Drosophila melanogaster (S2 cells) | 08.10.09 | —       | n.a.                     | [12]|
| 3MPH   | 2.05           | Drosophila melanogaster (S2 cells) | 27.04.10 | Aminoguanidine | Mechanism-based, Kn = 140 nM | [12]|

1 Not applicable due to the absence of inhibitors in the crystallographic unit. 2 Inhibition constants are not known.

4.1.1. Irreversible Complex of 2HP with hVAP-1

The X-ray structure for the extracellular part (residues 29-763) of hVAP-1 in complex with 2HP was solved at 2.9 Å resolution by Jakobsson et al. in 2005 (PDB code 2C11; [7]). The crystals were obtained by soaking the crystals of the holoenzyme (PDB code 2C10) with 5 mM CuCl2 and 8 mM 2HP. Due to the addition of CuCl2, additional Cu2+ ions were detected, and one of them interacts with the residues in the Arg726-Gly725-Asp728 hairpin loop, changing its conformation, which likely causes the lack of 34 C-terminal residues (729-763). The resulting complex structure also lacks large portions of the N-terminal residues 29-57. Despite these non-natural features, the 2HP adduct in the complex structure exists primarily as a hydrazone and shows how 2HP interacts with the catalytic site (Figure 4A). The TPQ is in off-copper conformation, where 2HP may react with C5 of TPQ. The catalytic Asp386 forms hydrogen bonds with the N2 and N3 nitrogens of 2HP, which stacks with Tyr384 and Phe389. Furthermore, Leu468 and Leu469 form hydrophobic interactions with 2HP. Since the computationally designed ligands have been planned to interact covalently with TPQ, the 2HP adduct structure has been most frequently used as a target in docking studies (Table 2).
4.1.2. Diverse Binding Modes Between Imidazole and hVAP-1

Two structures in complex with imidazoles were obtained when soluble hVAP-1 was extracted from human serum and crystallized in imidazole containing buffer [9]. Both of them similarly interact with two imidazoles that inhibit the enzymatic activity; the first one by binding to TPQ and the second one by blocking access to the active site. Both structures were crystallized under similar conditions but, interestingly, have the TPQ cofactor in different conformations. In one of them, TPQ is in the off-copper conformation, and the imidazole is covalently bound to TPQ (Figure 4B; PDB code 2Y74), whereas in the other one TPQ is in the on-copper conformation and the imidazole binds non-covalently to it (Figure 4C; PDB code 2Y73). Compared to the 2HP complex (Figure 4A), the first imidazole makes only one hydrogen bond with Asp386 and stacks between Tyr384 and Leu468 in both complexes (Figure 4B,C). Despite the different conformation of TPQ, the binding site of the non-covalently bound imidazole totally overlaps with the covalently bound imidazole and both N1 and N3 form hydrogen bonds to O₂ of TPQ and Asp386, respectively (Figure 4C). The second imidazole (yellow; Figure 4D) stacks with Tyr176, makes hydrophobic interactions with Leu469, Phe368, and Leu447 of Arm I from the other monomer, and its N3 forms a hydrogen bond with the hydroxyl group of Tyr394. In both the off-copper (Figure 4D) and on-copper (Figure 4E,F) structures, the second imidazole has the same binding site but the hydrogen bonding network with Thr212 is different in monomer B of the on-copper complex (Figure 4F). In monomer A of both complexes and monomer B of the off-copper
complex, the N1 nitrogen makes a water-mediated hydrogen bond with the main chain nitrogen of Thr212 (Figure 4D,E). In chain B of the on-copper complex, the side chain of Thr212 has a different conformation, and its hydroxyl group forms an additional hydrogen bond with the water molecule that interacts with N1 of the second imidazole (magenta, Figure 4F). Thus, the binding mode of the second imidazole differs in the monomers of hVAP-1 when the first imidazole is bound non-covalently to on-copper TPQ (Figure 4D,F). The closest distance between the two imidazoles is 7.5 Å.

4.2. Mechanism-Based Inhibitors

4.2.1. Hydrazines

Nurminen et al. (2011) [78] used the 2HP–hVAP-1 complex as a target for covalent docking of modified hydrazines (Table 3). The stacking interactions with Tyr384 and Phe389 formed by compound R1 are equal to those formed between 2HP and hVAP-1 (Figure 4A), but the additional hydroxyl group of R1 forms a hydrogen bond with the catalytic Asp386. The addition of a larger hydrophobic group to the C2 position of the hydrazines increased the selectivity of the inhibitors towards hVAP-1 over monoamine oxidase (MAO). Compounds R2 and R3 differ by the N-methyl group of R3, which changed the binding mode in such a way that the methyl group points towards Leu469. Therefore, the hydrogen bond between the same nitrogen and Asp386 that occurs in R2 is lost in R3, and this allows better hydrophobic interactions for the C2 substituent in R3. Thus, computational modeling explained the better binding affinity of R3 compared to R2. The docking studies combined with molecular dynamics simulations revealed that the flexibility of Met211, which is part of the hydrophobic pocket formed by Tyr384, Phe389, Tyr394, Leu468, and Leu469 (Figure 4A), allows accommodation of larger hydrophobic groups and even aromatic ring (compounds 11a–d) to the C2 position. La Jolla Pharmaceutical has been developing another hydrazine compound, namely LJP1207, with phenylpropenyl moiety attached to the hydrazine group. Initially, it showed promising results in a series of animal models, including autoimmune encephalomyelitis [52], chronic inflammation modeling ulcerative colitis [53], transient forebrain ischemia [86], and liver cancer [87]. However, due to its potentially toxic allylhydrazine structure, further development of LJP1207 was discontinued. In general, the safety issues related to the development of hydrazine derivatives have inspired hVAP-1 targeted inhibitor development towards other types of inhibitors [32].

4.2.2. Thiazoles

Inoue et al. [79] identified a thiazole hit compound with an IC50 value of 3.5 µM for hVAP-1 inhibition using high-throughput screening (HTS) and structure-activity relationship (SAR) studies. The developed thiazole compounds have a guanidine moiety that mimics a substrate Schiff base intermediate complex with TPQ. In accordance, the best compound R5 of the study had unsubstituted quinidine and 0.23 µM hVAP-1 inhibition. When R5 was covalently docked to the N1 nitrogen of the 2HP adduct (PDB code 2C11), the guanidine moiety established a tight hydrogen-bonding network with Asp386 providing a structural explanation for its importance as an unsubstituted functional group (Table 3). The sulfur atom in the thiazole ring formed a hydrogen bond with the backbone nitrogen of Thr210 and the amid group a proton–π interaction with Tyr176. Compound R5 was further analyzed by an in vivo test, and it was proved to be an inhibitor of macular edema [81]. It also exhibited improved binding to rat VAP-1 (rVAP-1) and more than 435-fold selectivity towards VAP-1 over DAO and MAO-B. The fact that compound R5 had significantly lower VAP-1 inhibitory activity in humans than in rats encouraged Inoue et al. [80] to develop the compound further. They used molecular docking together with pharmacophore modeling and combined features of R5 and another compound from HTS, which did not have a guanidinyl group. Series of thiazole and pyrazole compounds were subjected to SAR studies where thiazole was found to have a better VAP-1 inhibitory potency over pyrazole. The results were also analyzed in light of the sequence comparison of rat and human VAP-1. As a result, compound R6 was first identified but it established weak inhibitory activity
for rVAP-1. Based on the sequence analysis and docking results, the methanesulfonylphenyl moiety of R6 locates near Leu447, and the corresponding Phe447 in the rVAP-1 causes a steric hindrance for binding. Thus, they designed compound R7 (U-V002) by changing the phenyl group in R6 to benzyl group, which increased inhibitory activity for rVAP-1 50-fold and hVAP-1 about 2-fold [80]. U-V002, developed by R Tech Ueno Ltd.® showed promising inhibiting potency towards both human and rat VAP-1 with IC50 ≈ 7 nM and 8 nM, respectively, with low effect on MAO-A and MAO-B (IC50 > 10 µM for both) [70]. U-V002 also showed promising anti-inflammatory and anti-neovascularization effects in animal models [71,73] and, furthermore, it was evaluated preclinically for the treatment of diabetic retinopathy [72]; unfortunately, current development status of the compound is unknown.

4.2.3. Indanols

Biotie Therapies Corporation developed a series of hydrazine indanols of which BTT2052 was a potent inhibitor of hVAP-1, and its binding mode was computationally studied by manual docking to TPQ [74]. It binds like other hydrazines (Figure 3A) and, similarly to the hydroxyl group of the C2 substituted hydrazines (4.2.1), the hydroxyl group of indanol forms a hydrogen bond with Asp386, while the rings form hydrophobic interactions with Met211, Tyr384, Phe389, and Leu469. Despite BTT2052 being a potent inhibitor of hVAP-1 and not inhibiting MAO, it was an effective inhibitor of hDAO and hRAO [74]. This is understandable in light of our current knowledge of human CAO active site channels [1], showing that the residues in the catalytic site are highly conserved and residues in the active site channel contribute to the subtype specificity. As a small inhibitor, BTT2052 does not interact with these residues in the active site channel. The same considerations are valid in the case of a highly similar molecular entity, BTT-2027, which was shown to have high selectivity to hVAP-1 over twenty test targets with Ki ≈ 54 nM [20]. Although no modeling studies have been published, it can be hypothesized to bind tightly to hDAO and hRAO in the same orientation as BTT2052 does.

4.2.4. H-Imidazol-2-Amines

Inoue et al. [81] continued their earlier work with thiazole compounds (4.2.2) intending to design compounds that bind better to hVAP-1, as the developed compound R5 [79] was a much better inhibitor of rat than hVAP-1. They first used the thiazole pharmacophore of compound R5 (named 2 in [81]) and optimized the phenylguanidine biostere, 1H-benzimidazol-2-amine (compound R8) to design compound R9 by synthesis and SAR of 1H-imidazol-2-amines compounds. The inhibitor VAP-1 activity of R9 was 19 nM towards human and 5.1 nM towards rat enzyme [81]. In their study, docking analysis of compound R8 suggested that its benzene ring is not optimally positioned in the active site of hVAP-1. Based on these results, they added a thiazole substituent in the 4-position of the benzene ring to create compound R9. The docking studies of R9 indicated that the stronger interactions formed by the aminothiazole moiety are responsible for its increased inhibitory activity compare to compound R5 (Table 2). Compound R9 was highly selective towards VAP-1 over other CAOs and MAOs, and it was orally active in a pathological rat model of macular edema [81]. Later, R9 proved not to be suitable for further clinical development due to its insufficient pharmacokinetic properties in rats [83].

4.2.5. Allylamines

Pharmaxis Ltd.® published their first paper on allylamine inhibitors of hVAP-1 in 2012 [54]. Their project was inspired by the irreversible haloallylamine inhibitor of MAO-B, mofegiline, the inhibition mode of which is hypothesized to rely on a covalently attached reactive intermediate that is alkylated to release fluorine, thus leading to irreversible inhibition [54]. In their study, modeling and SAR were systematically used to design a highly potent compound R10 (PXS-4159) with promising pharmacokinetic profile and good in vitro and in vivo inhibitory activity. It showed a high preference towards hVAP-1 as compared to MAO-A, MAO-B, and hDAO, which is evident from the IC50 values of 10 nM vs. >30, 1.64, and >30 µM, respectively [54]. Modeling showed a crucial role for the hydrophobic interactions between the cyclohexyl moiety and Phe173-Tyr394 for the stabilization of
R10 in the binding pocket. To the best of our knowledge, PXS-4159 is still subjected to the preclinical tests. After that, Pharmaxis reported several other haloallylamines (Table 1). In PXS-4728A (later renamed to BI 1467335), the cyclohexyl group was changed to the other lipophilic (isobutyl) moiety. In 2019, BI 1,467,335 completed the Phase II clinical trials for the treatment of non-alcoholic fatty liver disease; however, no results have been released yet. Another haloallylamine, PXS-4681A, which is no longer under development, has a highly polar sulfonamide group instead of the lipophilic cyclohexyl moiety, which can establish multiple hydrogen bonds with the same Tyr394 residue. Moreover, La Jolla Pharmaceutical Company® has been evaluating haloallylamine LJP1586, which has high potency against both human and rat VAP-1 with IC50 values between 4 and 43 nM [22]. It showed promising results in animal models of subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction [63], intracerebral hemorrhagic stroke [61], multiple sclerosis [60], and temporary middle cerebral artery occlusion [64]. However, no data on the further clinical development of the compound are available.

4.2.6. Glycine Amides

Yamaki et al. (2017) [83] reported the development of their first VAP-1-targeted glycine amide derivatives as their previous work on thiazole substituted 1H-imidazol-2-amine (compound 37b in Table 2) was not suitable for further clinical development. The first glycine amide scaffold with micromolar hVAP-1 inhibitor activity was identified by screening their in-house compound library, and its structural optimization was conducted using an extensive synthesis of glycine amide derivatives combined with SAR. Thereafter, they found that compound R12, a tertiary amide derivative of the initial compound, had increased stability but much weaker in vitro potency to human and rat VAP-1 [83]. At this point, molecular docking of R12 with hVAP-1 was used to model the Schiff base intermediate with TPQ. Based on the molecular docking results, substituents to the 4-position of the most solvent-exposed phenyl ring were designed and synthesized. Based on the parallel SAR and artificial membrane permeability assay, compound R13 (Table 2) showed the best properties and was selected for further studies. Next, the binding mode of R13 was predicted using docking analysis and its binding pose shown to be similar to that of R12. The morpholine group at the 4-position of the phenyl ring protrudes from the active site cavity to the solvent between Arm I from the other monomer and Phe173 of D3 and the stacking interaction of the phenyl ring with Leu447 of Arm I is preserved like in R12 [83]. Further studies of compound R13 (Compound 1 in [84]) revealed that it had species-specific binding properties and was a better inhibitor of rat than human VAP-1. Similarly to the thiazole design, the sequence comparison of human and rat VAP-1 suggested that Leu447/Phe and Phe173/Thr differences are responsible for the weaker binding to hVAP-1. As the 4-position of the phenyl ring had been proven optimal in the previous study [83], replacement of the phenyl ring by various heteroaromatic rings was tested [84]. Several rounds of synthesis and SAR revealed compound R14 with a nanomolar binding activity to human and rat VAP-1 and reduced CYP inhibition. The docking study predicted good stacking interactions between the first phenyl ring and Leu469, pyrimidine and Leu447 of ArmI, and piperazine and Tyr394. Furthermore, the chlorine of the surface phenyl group interacts with Asp446. Ex vivo and in vivo studies suggest that R14 could be suitable for treating diabetic nephropathy [84].

4.3. Reversible Inhibitors

4.3.1. Pyridazinones

The hVAP-1–imidazole complex structures (PDB core 2Y73 and 2Y74) revealed a novel, secondary binding site for imidazole in the active site channel, which inspired the design of reversibly binding pyridazinone inhibitors [10]. Three of the designed inhibitors were studied in more detail, and the X-ray structures in complex with hVAP-1 were solved for R15 (IC50 70 µM; PDB code 4BTX), R16 (IC50 290 µM; PDB code 4BTW), and R17 (IC50 20 µM; PDB code 4BTY) (Table 3). The binding mode of the pyridazinones is similar and the 2.8 Å X-ray structure of the R15–hVAP-1 complex is shown as an
example of the binding mode (Figure 5). For all the pyridazinones, the pyridazine ring stacks between
Tyr176 and Leu447 from Arm I of the other monomer and makes hydrophobic interactions with
Phe227. In addition, the carbonyl group of pyridazinone forms a hydrogen bond with the hydroxyl

Figure 5. Pyridazinone binding to hVAP-1; (A) binding mode of pyridazinone R15 to chain A; (B)

binding mode of pyridazinone R15 to chain B. Leu447 from the Arm I of chain A (cyan, behind R15) is

not labeled; (C) comparison of pyridazinone R15 (pink) and the second imidazole (orange) binding to

chain B of hVAP-1 (grey). The point of view is rotated to show the hydrogen bonding interactions of

R15 (black dashed lines) and imidazole (orange). Labels for Tyr176 (pink), Leu447, and Tyr448 (cyan)

stacking with the inhibitors are not shown for clarity.

A modeling study by Bligt-Lindén et al. [88] revealed the differences in the secondary imidazole

binding site organization in human and monkey VAP-1 vs. rat and murine VAP-1. The width of the

entry channel in rat and murine VAP-1 was limited by Phe447, which is not the case for the human and

monkey enzyme with a smaller leucine residue. Besides, rodents have larger residues than primates in

positions 177 (Gln vs. Leu) and 180 (Gln vs. Asp), which makes the channel even narrower. There

are also additional differences in the composition of residues lining the active site channel that might

affect ligand binding. Phe173 and Leu177 in hVAP-1 are changed to polar residues in rodent enzymes:

Thr173 in mVAP-1, Asp173 in rVAP-1, and Gln177 in both rodent VAP-1s. Rats also have larger Thr in

position 761 as compared to Ser761 in hVAP-1 and Ala761 in mVAP-1. All these residues are located

at the entrance of the active site channel and might also affect ligand recognition. This finding can

explain the high specificity of compounds R15, R16, and R17 to hVAP-1 as compared to the murine

VAP-1 (mVAP-1) [10]. For example, methylpiperazine moiety of R17 is in close contact with residues
761 and 177, its phenyl ring interacts with residues 173, 177 and 447 and its imidazole ring with residue 180, which differs between human and rodent VAP-1. The largest and most lipophilic compound R17 shows the best binding profile, which is in agreement with the hypothesis that primate VAP-1 prefers bulkier and more hydrophobic ligands than rodent VAP-1 [88].

4.3.2. Phenyl-Piperidinyl Amine

Before the publication of pyridazinone complexes, Emanuela et al. (2012) reported docking and inhibitor activity studies of R11 as a plausible skeleton for the design of reversibly binding inhibitors of hVAP-1 [82] (Table 2). Based on the docking results, R11 (about 100 µM inhibitor) was predicted to have two different binding modes. In one of them, the inhibitor aligns with the opening of the active site cavity, reaching towards Asp180. In the other binding mode, one end of R11 similarly aligns with the opening, but the other one intrudes to the active site and stacks between Phe389 and Leu469.

5. hDAO as an Off-Target

5.1. Biological Function

DAO, with distinct specificity for diamine substrates, was originally described as a histaminase in 1929 [89]. hDAO is the main enzyme catabolizing ingested histamine [26,90]. Unlike VAP-1, DAO is a soluble protein, which is released from kidney and intestinal epithelial cells and requires an external stimulus [91]. Pathologies that limit DAO secretion from basolateral vesicles, e.g., inflammation and degenerative intestinal disorders, lead to hDAO deficiency [26,92,93]. Furthermore, low DAO levels are known to be caused by genetic mutations. The preferred substrates for DAO are histamine (Km = 2.8 ± 0.07 µM), 1-methylhistamine (Km = 3.4 ± 0.3 µM), and putrescine (Km = 20 ± 1 µM) [25]. Of the DAO substrates, histamine regulates several physiological processes (e.g., gastric acid secretion, central nervous system functioning, hypersensitivity reactions, bronchial asthma, tumorigenesis, and multiple elements of immune regulation). hDAO has a central role in histamine intolerance, which is caused by histamine-rich food, alcohol, or drugs that release histamine or inhibit hDAO and, thus, leads to an excess of histamine and symptoms similar to an allergic reaction in the patients [26]. hDAO deficiency has been described in patients with atopic eczema, chronic urticaria, chronic abdominal pain or inflammatory bowel disease, migraines, and asthma [94–99]. Histamine also induces contractions and spontaneous abortions when injected into pregnant animals [28,100–102]. The enzymatic activity of DAO increases several 100-fold during pregnancy, and low DAO activity in the first trimester has been associated with a 16-fold increased risk of fetal death [28,103]. Women suffering from early-onset preeclampsia (delivery before week 34 associated with a 10-fold higher risk of mortality [104]) were shown to have significantly lower hDAO levels in the first trimester of pregnancy compared to healthy controls, which is believed to be damaging for the vascular remodeling modulating the uteroplacental blood flow [105]. Based on a mice study, DAO regulates the homeostatic histamine and putrescine levels, which is important in embryo implantation [106].

5.2. Off-Target Function

Despite strictly controlled development processes, any drug bears a risk of unintended and potentially harmful responses, i.e., adverse drug reactions (ADRs) [107]. Commonly, ADRs are caused by the drug molecule interacting with targets beyond the one(s) it was designed for, so-called off-targets [108]. DAO is an important off-target due to its role as the frontline enzyme for clearing extra-cellular histamine [11,26]. A drug molecule with an off-target activity that causes inhibition of hDAO can cause a rise in histamine levels and related ADRs resembling allergic reactions (e.g., headaches, gastrointestinal disorders, skin reactions, flushing, sneezing, asthma-like wheezing, muscle aches, hypotension, and arrhythmias) and, at its worst, anaphylactic shock. Inhibition of pig and sheep DAO with the potent and irreversible inhibitor aminoguanidine, followed by oral challenge with reasonable levels of histamine, significantly induced anaphylactic shock-like symptoms and increased
death rates compared to control animals [27,109]. Relevant to humans, high levels of histamine are found in some common food (e.g., cheese, sausages, yogurts, etc.), in alcohol, and can also be induced by drugs releasing histamine or blocking DAO [26,110]. Inhibition of DAO can also increase the risk of developing intestinal carcinoma, indicating that prolonged use of drugs inhibiting DAO may elevate the cancer risk [111,112]. The patients of atopic eczema, chronic urticaria, chronic abdominal pain or inflammatory bowel disease, migraines, and asthma [94–99] that have hDAO deficiency, as well as pregnant women, form high-risk groups for severe ADRs if treated with drugs causing histamine release or drugs having an off-target and activity-blocking effect on hDAO. Currently, aminoguanidine, berenil, pentamidine, and metformin have been indicated to have off-target, activity-blocking effects on hDAO, but many more drugs are expected to show similar behavior, thereby potentially causing severe ADRs [13,27,113].

5.3. Unintended Drug–hDAO Interactions at the Atomic Level

Berenil and pentamidine are diamine derivatives, which are drugs for treating trypanosomiasis and pneumocystis pneumonia infections, interact with the minor groove of DNA [114,115]. Both of them have amidophenyl moieties at the ends but vary in the length and chemical nature of the central linkers. The X-ray structures of hDAO in complex with berenil (PDB code 3HIG) and pentamide (PDB code 3HII) revealed the binding mode of the inhibitors [11] (Table 3, Figure 6). Aminoguanidine is a potent inhibitor of DAO with reported IC50 values of ≈ 30 μM [116] and ≈ 150 nM [12]. It is an experimental therapeutic, which prevents advanced glycation end product (AGE) formation [117,118]. Several clinical trials conducted on aminoguanidine indicated that it would be beneficial for treating patients with diabetic nephropathy but also caused many adverse reactions in high doses, e.g., flu-like symptoms, abnormal kidney function tests, and effects on the gastrointestinal tract [117–119]. In clinical therapy, the peak plasma concentration of aminoguanidine is ≈ 50 μM [117], which is much higher than the IC50 of hDAO and enough to inhibit the majority of peripheral hVAP-1 (IC50 ≈ 30 μM) as well [12]. Aminoguanidine may, however, be used in small doses for treating diabetic nephropathy as well as other AGE-related disorders 118. In the X-ray structure complexes, pentamidine and berenil do not interact covalently with the TPQ cofactor (Figure 6A,B) but aminoguanidine forms a covalent adduct with TPQ (Figure 6C). Its guanidinium group makes polar interactions with Asp373 and stacks between Val458, Tyr371, and Trp376 (Figure 6C). Metformin, a drug used for the treatment of type 2 diabetes, causes gastrointestinal side effects for 30%–50% of patients, and 5% has such severe symptoms that they discontinue the usage of metformin [113]. Based on the molecular structure of metformin (Figure 6C), it also interacts covalently with TPQ but likely forms even more interactions.

![Figure 6](https://example.com/figure6.png)

**Figure 6.** hDAO interactions with off-targets. (A) Pentamidine; (B) Berenil; (C) Aminoguanidine. Phe435 of Arm I from the other monomer is shown in orange.

The binding modes of pentamidine (Figure 6A) and berenil (Figure 6B) resemble each other but also have apparent differences. In these complex structures, TPQ is in on-copper conformation and does not make direct contact with the inhibitors. In both of the inhibitors, the buried amidinium group interacts with the catalytic Asp373, and the connected phenyl ring stacks with Tyr371 and
Trp376. Pentamidine binds in a U-shaped form and the other amidinium group forms hydrogen bonds with Ser380 and the main chain of Glu377 and Trp376. Its central linker region does not make any significant interactions. Berenil extends straight out from the active site, and the central triazine linker is positioned between Tyr459 and Asp186, and Asp186 makes electrostatic interactions with the nitrogens in the triazine moiety. The second phenyl ring stacks between Phe148 and Phe435 of ArmI. The second amidinium group is exposed to solvent near the surface opening of the active site channel.

6. Special Considerations in hVAP-1-Targeted Drug Design

6.1. Species-Specific Features in VAP-1 Ligand Recognition

Due to the fact that rodents are routinely used for estimating inhibitor potency, it is crucial to elucidate the difference in ligand binding among human, mouse, and rat VAP-1. Sequence analysis shows a high degree of similarity between hVAP-1 and rodent VAP-1s: hVAP-1 is 80% identical with rVAP-1 and 83% identical with mVAP-1 [120]. Nevertheless, species differences in ligand binding to VAP-1 were documented using SSAO activity in plasma, umbilical artery, or homogenized tissues more than two decades ago [121,122]. In contrast to the very first modeling study by Marti et al. [123], who failed to find the sequence basis for the observed species-specific enzymatic properties of VAP-1, Bligt-Lindén et al. [88] showed that hVAP-1 has broader and more hydrophobic active site channel than rodent VAP-1; thus, hVAP-1 should prefer larger and more hydrophobic inhibitors. Indeed, there are no major differences in the active site near TPQ, while the active site channel differs between human and rodent VAP-1 [88]. The different cavity architecture is caused by sequence variations in positions 173, 177, 180, and 761 from one chain and 447 from the other one, which are responsible for the species-specific differences in inhibitor binding (Figure 7A) [88]. Highly species-specific pyridazinone inhibitors R15, R16, and R17 with a preference for hVAP-1 were recently structurally studied [10]. Comparison of the X-ray structures of hVAP-1 complexes and modeling of the inhibitor complexes for rodent and monkey VAP-1 suggested that the same residues are responsible for the species-specific inhibitor binding properties of pyridazinones (Figure 7A). Since these residues are scattered all over the active site channel, it is a challenging task to design an equally potent inhibitor towards primate and rodent VAP-1 [10].

Figure 7. (A) Species-specific residues in the VAP-1 active site channel. Residues in rat (wheat)/mouse (yellow) VAP-1 are listed below the residue labels of hVAP-1 (cyan/pink). The catalytic center around TPQ is totally conserved, and the residue differences concentrate on the Arm I and the first helix of D3; (B) key residue differences between hVAP-1 and hDAO (green/orange). The Aminoguanidine–hDAO complex (green; PDB code 3MPH) superimposed with hVAP-1 structure (PDB code 2C10). Binding sites depicted similarly as in Figure 3.

Modeling study by Inoue et al. [81] suggested that differences in residues 173 (Phe in hVAP-1 vs. Thr in rVAP-1) and 447 (Leu vs. Phe) could be responsible for a species-specific inhibitor potency of R6.
Based on their hypothesis, the highly hydrophilic Asp173 in mVAP-1 can be responsible for a high preference for hVAP-1 over mVAP-1 [88]. Foot et al. [54] modeled the binding orientation of compound R10 that is structurally close to PXS-4728A and revealed the essential role of hydrophobic interactions with Phe173 and Tyr394. Based on their analysis, the species-specificity in position 173 (hydrophobic Phe in hVAP-1, polar Thr in rVAP-1, and negatively charged Asp in mVAP-1; Figure 7A) is a probable reason for a slightly higher potency of PXS-4728A towards hVAP-1 as compared to rodent VAP-1. Kubota et al. [120] recently performed extensive biochemical comparison of inhibitor potency toward human, mouse and rat VAP-1 and revealed apparent species-specific differences: semicarbazide was 10 and 3 times more potent toward hVAP-1 (85.9 µM) as compared to rVAP-1 (993 µM) and mVAP-1 (295 µM), respectively; in contrast, hydralazine more efficiently inhibited rodent VAP-1 than hVAP-1 (1.2 µM for rVAP-1 and 3.1 µM for mVAP-1 vs. 7.8 µM for hVAP-1). Another small inhibitor LJP-1207 showed less species-specificity: it was 2 and 2.5 times more potent towards hVAP-1 than to rVAP-1 and mVAP-1, respectively (252 nM vs. 120 nM and 102 nM). The slightly bulkier inhibitor PXS-4728A showed a weak preference for hVAP-1, while large compound R7 developed by Astellas showed a slight preference for hVAP-1 (23 nM) over the rat ortholog (50 nM) but much weaker binding to the mouse ortholog (414 nM). As a summary of the previous studies on species-specific binding properties of hVAP-1 inhibitors, it is clear that computational methods should be used to predict the species-specific binding properties in hVAP-1-targeted ligand design. In general, the likelihood of species-specificity increases with enlarged ligand size and is most prominent for those ligands that interact with the active site channel farther away from the catalytic site [1].

6.2. The Risk for Interaction with Other CAO Sub-Family Members

In addition to species-specific binding properties (Table S2), differences in the expression profile of the CAO sub-families should be considered when model organisms are selected for in vivo studies [1]. As an example, the pyridazinone inhibitors had a similar in vitro potency against VAP-1 from human and cynomolgus monkey [10], but cynomolgus monkey is not a good model organism for in vivo studies since it also has soluble plasma amine oxidase (SAO; AOC4), the closest CAO family member to VAP-1 [1]. In fact, of all studied primates, only human and gorilla lacked SAO [1]. Of rodents, mice had the same CAO sub-families (VAP-1, DAO, and RAO) as humans, whereas rats have only VAP-1 and DAO [1]. Thus, the best preclinical model organism for hVAP-1-targeted ligand design would be mouse [1] and, naturally, transgenic mouse overexpressing human VAP-1 on endothelium is an even better alternative for in vivo studies to avoid both sub-family cross-reactions and species-specific binding properties [17].

Of the CAO sub-families expressed in human, RAO is also a monoamine oxidase, but it has a different substrate preference profile, and its enzymatic activity has been detected only in the eye [3]. DAO, in turn, is a known off-target and interfering with its normal function as histaminase with drug molecules results in ADRs [11,113,117–119]. At the moment, to the best of our knowledge, modeling studies on VAP-1-targeting inhibitors that could result in off-target interactions with DAO have not been published. The X-ray structure of hDAO has been solved in complex with the experimental drug aminoguanidine, which inhibits both DAO and VAP-1. Aminoguanidine inhibits DAO significantly better than VAP-1, but its clinically used concentration also inhibits hVAP-1 [116]. Comparison of the hDAO-aminoguanidine complex with hVAP-1 structure shows that of the interacting residues only Tyr371 is conserved while the Trp376/Phe389, Val458/Leu468, and Tyr459/Leu469 replacements likely contribute to its weaker binding into hVAP-1 (Figure 7B). The position corresponding to Asp186 in hDAO (Figure 7A) is highly conserved within each CAO subfamily (Thr212 in VAP-1, His in RAO and Asn in SAO) and, thus, suggested to be important for the substrate selectivity of CAOs [11]. The corresponding Thr212, together with Thr210 and Tyr394 in hVAP-1 (Phe184 and Val381 in hDAO), is involved in imidazole and pyridazinone binding. In general, the residues in the active site channel of hVAP-1 are not conserved in hDAO, and furthermore, the tip of Arm 1 has a totally different conformation in these two CAOs. However, it is advisable to test the binding of designed hVAP-1...
inhibitors for their effect on hDAO as the catalytic site is highly conserved and small adjustments and rearrangements of side chain conformations in the active site channel might allow their binding to hDAO as well.

Supplementary Materials: The following supplements are available online, Table S1: List of traditional and IUPAC names of the compounds referred to in the text; Table S2: List of amino acids relevant to inhibitor binding that differ among VAP-1 orthologs and copper-containing amine oxidase sub-families.

Author Contributions: Conceptualization, T.A.S. and S.J.; writing—original draft preparation, S.V., K.M.D., S.J., T.A.S.; writing—review and editing, S.V., K.M.D., S.J., T.A.S.; visualization, T.A.S.; supervision, T.A.S.; project administration, S.V., T.A.S.; funding acquisition, S.J., T.A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Sigrid Juselius Foundation (T.A.S.), the Magnus Ehrnrooth foundation (T.A.S), the Tor, Joe, and Pentti Borgs Foundation (T.A.S.), Medicinska Understödsföreningen Liv och hälsa (T.A.S.), and the Academy of Finland (No. 288534 T.A.S.).

Acknowledgments: We thank the bioinformatics (J.V. Lehtonen), translational activities, and structural biology infrastructure support from Biocenter Finland and Instruct-FI and CSC IT Center for Science for computational infrastructure support at the Structural Bioinformatics Laboratory, Åbo Akademi University.

Conflicts of Interest: S.J. owns stocks of Faron Ventures and Faron Pharmaceuticals. The other authors declare no conflict of interest.

Abbreviations

2HP 2-hydrazinopyridine;
ADRs adverse drug reactions;
AOC1 hDAO human diamine oxidase;
AOC2 hRAO retina-specific amine oxidase;
AOC3 hVAP-1 vascular adhesion protein-1;
CAO copper-containing amine oxidase;
DAO diamine oxidase;
HTS high-throughput screening;
MAO monoamine oxidase;
mVAP-1 murine ortholog of vascular adhesion protein-1;
PDB Protein Data Bank;
PET positron emission tomography;
rVAP-1 rat ortholog of vascular adhesion protein-1;
TPQ topaquinone.

References

1. Lopes de Carvalho, L.; Bligt-Lindén, E.; Ramaiah, A.; Johnson, M.S.; Salminen, T.A. Evolution and functional classification of mammalian copper amine oxidases. *Mol. Phylogenet. Evol.* 2019, 139, 106571. [CrossRef] [PubMed]

2. Schwelberger, H. Diamine oxidase (DAO) enzyme and gene. In *Histamine: Biology and Medical Aspects*; Falus, A., Ed.; SpringMed Publishing: Budapest, Hungary, 2004; pp. 43–52.

3. Kaitaniemi, S.; Elovaara, H.; Grön, K.; Kidron, H.; Liukkonen, J.; Salminen, T.; Salmi, M.; Jalkanen, S.; Elimä, K. The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. *Cell. Mol. Life Sci.* 2009, 66, 2743–2757. [CrossRef] [PubMed]

4. Smith, D.; Salmi, M.; Bono, P.; Hellman, J.; Leu, T.; Jalkanen, S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. *J. Exp. Med.* 1998, 188, 17–27. [CrossRef] [PubMed]

5. Dawkes, H.; Phillips, S. Copper amine oxidase: Cunning cofactor and controversial copper. *Curr. Opin. Struct. Biol.* 2001, 11, 666–673. [CrossRef]

6. Nymalm, Y.; Kidron, H.; Söderholm, A.; Viitanen, L.; Kaukonen, K.; Pihlavisto, M.; Smith, D.; Veromaa, T.; Airenne, T.; Johnson, M.; et al. Crystallization and preliminary X-ray analysis of the human vascular adhesion protein-1. *Acta Cryst. D Biol. Cryst.* 2003, 59, 1288–1290. [CrossRef]
7. Jakobsson, E.; Nilsson, J.; Ogg, D.; Kleywegt, G.J. Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. Acta Cryst. Sect. D Biol. Cryst. 2005, 61, 1550–1562. [CrossRef]  
8. Airenne, T.T.; Nymalm, Y.; Kidron, H.; Smith, D.J.; Pihlavisto, M.; Salmi, M.; Jalkanen, S.; Johnson, M.S.; Salminen, T.A. Crystal structure of the human vascular adhesion protein-1: Unique structural features with functional implications. Protein Sci. 2005, 14, 1964–1974. [CrossRef]  
9. Elovaaara, H.; Kidron, H.; Parkash, V.; Nymalm, Y.; Blixt, E.; Ollikka, P.; Smith, D.J.; Pihlavisto, M.; Salmi, M.; Jalkanen, S.; et al. Identification of two imidazole binding sites and key residues for substrate specificity in human primary amine oxidase AOC3. Biochemistry 2011, 50, 5507–5520. [CrossRef]  
10. Bligt-Lindén, E.; Pihlavisto, M.; Szatmári, I.; Otwinowski, Z.; Smith, D.J.; Lázár, L.; Fülöp, F.; Salminen, T.A. Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): Old target-new inhibition mode. J. Med. Chem. 2013, 56, 9837–9848. [CrossRef]  
11. McGrath, A.P.; Hilmer, K.M.; Collyer, C.A.; Shepard, E.M.; Elmore, B.O.; Brown, D.E.; Dooley, D.M.; Guss, J.M. Structure and inhibition of human diamine oxidase. Biochemistry 2009, 48, 9810–9822. [CrossRef]  
12. McGrath, A.; Caradoc-Davies, T.; Collyer, C.; Guss, J. Correlation of active site metal content in human diamine oxidase with trihydroxyphenylalanine quinone cofactor biogenesis. Biochemistry 2010, 49, 8316–8324. [CrossRef] [PubMed]  
13. McGrath, A.P.; Hilmer, K.M.; Collyer, C.A.; Dooley, D.M.; Guss, J.M. A new crystal form of human diamine oxidase. Acta Cryst. Sect. F Struct. Biol. Commun. 2010, 66, 137–142. [CrossRef] [PubMed]  
14. Salmi, M.; Jalkanen, S. Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread. FÉBS Lett. 2011, 585, 1543–1550. [CrossRef] [PubMed]  
15. Salmi, M.; Jalkanen, S. Ectoenzymes controlling leukocyte traffic. Eur. J. Immunol. 2012, 42, 284–292. [CrossRef]  
16. Salmi, M.; Jalkanen, S. Ectoenzymes in leukocyte migration and their therapeutic potential. Semin. Immunopathol. 2014, 36, 163–176. [CrossRef]  
17. Salmi, M.; Jalkanen, S. Vascular adhesion protein-1: A cell surface amine oxidase in translation. Antioxid. Redox Signal. 2019, 30, 314–332. [CrossRef]  
18. Aalto, K.; Autio, A.; Kiss, E.A.; Elima, K.; Nymalm, Y.; Veres, T.Z.; Marttila-Ichihara, F.; Elovaaara, H.; Saanijoki, T.; Crocker, P.R.; et al. Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood 2011, 118, 3725–3733. [CrossRef]  
19. Elovaaara, H.; Parkash, V.; Fair-Mäkelä, R.; Salo-Ahen, O.M.H.; Guédez, G.; Bligt-Lindén, E.; Grönholm, J.; Jalkanen, S.; Salminen, T.A. Multivalent interactions of human primary amine oxidase with the v and C22 domains of sialic acid-binding immunoglobulin-like lectin-9 regulate its binding and amine oxidase activity. PLoS ONE 2016, 11, e0166935. [CrossRef]  
20. Koskinen, K.; Vainio, P.; Smith, D.J.; Pihlavisto, M.; Ylä-Herttuala, S.; Jalkanen, S.; Salmi, M. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004, 103, 3388–3395. [CrossRef]  
21. Merinen, M.; Irjala, H.; Salmi, M.; Jaakkola, I.; Hanninen, A.; Jalkanen, S. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am. J. Pathol. 2005, 166, 793–800. [CrossRef]  
22. O’Rourke, A.; Wang, E.; Miller, A.; Podar, E.M.; Scheyhing, K.; Huang, L.; Kessler, C.; Gao, H.; Ton-Nu, H.-T.; Jones, S.D.; et al. Antiinflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J. Pharm. Exp. Ther. 2008, 324, 867–875. [CrossRef] [PubMed]  
23. Noonan, T.; Lukas, S.; Peet, G.; Pelletier, J.; Panzenbeck, M.; Hanidu, A.; Mazurek, S.; Wasti, R.; Rybina, I.; Roma, T.; et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am. J. Clin. Exp. Immunol. 2013, 2, 172–185. [PubMed]  
24. Jones, B.; Kearns, G. Histamine: New thoughts about a familiar mediator. Clin. Pharm. 2011, 39, 189–197. [CrossRef] [PubMed]  
25. Elmore, B.; Bollinger, J.; Dooley, D. Human kidney diamine oxidase heterologous expression, purification, and characterization. J. Biol. Inorg. Chem. 2002, 7, 565–579. [CrossRef] [PubMed]  
26. Maintz, L.; Novak, N. Histamine and histamine intolerance. Am. J. Clin. Nutr. 2007, 85, 1185–1196. [CrossRef] [PubMed]
27. Sattler, J.; Hafner, D.; Klotter, H.; Lorenz, W.; Wagner, P. Food-induced histaminosis as an epidemiological problem: Plasma histamine elevation and haemodynamic alterations after oral histamine administration and blockade of diamine oxidase (DAO). [Agents Actions 1988, 23, 361–365. [CrossRef]

28. Maintz, L.; Schwarzer, V.; Bieber, T.; Van der Ven, K.; Novak, N. Effects of histamine and diamine oxidase activities on pregnancy: A critical review. Hum. Reprod. Update 2008, 14, 485–495. [CrossRef]

29. Heuts, D.P.H.M.; Gummadova, J.O.; Pang, J.; Rigby, S.E.J.; Scrutton, N.S. Reaction of Vascular Adhesion Protein-1 (VAP-1) with primary amines: Mechanistic insights from isotope effects and quantitative structure-activity relationships. J. Biol. Chem. 2011, 286, 29584–29593. [CrossRef]

30. Klinman, J.P. The multi-functional topa-quinone copper amine oxidases. Biochim. Biophys. Acta 2003, 1647, 131–137. [CrossRef]

31. Shepard, E.M.; Dooley, D.M. Inhibition and oxygen activation in copper amine oxidases. Acc. Chem. Res. 2015, 48, 1218–1226. [CrossRef]

32. Pannecoek, R.; Serruys, D.; Benmeridja, L.; Delanghe, J.R.; Van Geel, N.; Speeckaert, R.; Speeckaert, M.M. Vascular adhesion protein-1: Role in human pathology and application as a biomarker. Crit. Rev. Clin. Lab. Sci. 2015, 52, 284–300. [CrossRef] [PubMed]

33. Murray, J.M.; Saysell, C.G.; Wilmot, C.M.; Tambyrajah, W.S.; Jaeger, J.; Knowles, P.; Phillips, S.E. The active site base controls cofactor reactivity in Escherichia coli amine oxidase: X-ray crystallographic studies with mutational variants. Biochemistry 1999, 38, 8217–8227. [CrossRef] [PubMed]

34. Green, E.L.; Nakamura, N.; Dooley, D.M.; Klinman, J.P.; Sanders-Loehr, J. Rates of oxygen and hydrogen exchange as indicators of TPQ cofactor orientation in amine oxidases. Biochemistry 2002, 41, 687–696. [CrossRef] [PubMed]

35. Mure, M.; Mills, S.A.; Klinman, J.P. Catalytic mechanism of the topa quinone containing copper amine oxidase. Biochemistry 2002, 41, 9269–9278. [CrossRef]

36. Dooley, D.M.; McGuirl, M.A.; Brown, D.E.; Turowski, P.N.; McIntire, W.S.; Knowles, P.F. A Cu(I)-semiquinone state in substrate-reduced amine oxidases. Nature 1991, 349, 262–264. [CrossRef] [PubMed]

37. Shepard, E.M.; Okonski, K.M.; Dooley, D.M. Kinetics and spectroscopic evidence that the Cu(I)-semiquinone intermediate reduces molecular oxygen in the oxidative half-reaction of Arthrobacter globiformis amine oxidase. Biochemistry 2008, 47, 13907–13920. [CrossRef]

38. Liu, Y.; Mukherjee, A.; Nahumi, N.; Ozbil, M.; Brown, D.; Angeles-Boza, A.M.; Dooley, D.M.; Prabhakar, R.; Roth, J.P. Experimental and computational evidence of metal-O2 activation and rate-limiting proton-coupled electron transfer in a copper amine oxidase. J. Phys. Chem. B 2013, 117, 218–229. [CrossRef]

39. Roth, J.P.; Klinman, J.P. Catalysis of electron transfer during activation of O2 by the flavoprotein glucose oxidase. Proc. Natl. Acad. Sci. USA 2003, 100, 62–67. [CrossRef]

40. Kivi, E.; Eima, K.; Aalto, K.; Nymalm, Y.; Auvinen, K.; Koivunen, E.; Otto, D.M.; Crocker, P.R.; Salminen, T.A.; Salmi, M.; et al. Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood 2009, 114, 5385–5392. [CrossRef]

41. Virtanen, H.; Autio, A.; Sintonen, R.; Liljenbäck, H.; Saanijoki, T.; Lankinen, P.; Mäkilä, J.; Käkelä, M.; Teuho, J.; Savisto, N.; et al. 68Ga-DOTA-Siglec-9—A new imaging tool to detect synovitis. Arthritis Res. 2015, 17, 305. [CrossRef]

42. Roivainen, A. Identifier NCT03755245. Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis (SIGLEC). Available online: https://clinicaltrials.gov/ct2/show/NCT03755245?term=VAP-1&country=FI&draw=2 (accessed on 20 January 2020).

43. Arndtz, K.; Corrigan, M.; Rowe, A.; Kirkham, A.; Barton, D.; Fox, R.; Llewellyn, L.; Athwal, A.; Wilkhu, M.; Chen, Y.; et al. Investigating the safety and activity of the use of BTI010 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTOE): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. BMJ Open 2016. [CrossRef] [PubMed]

44. De Zeeuw, D.; Renfurm, R.W.; Bakris, G.; Rossing, P.; Perkovic, V.; Hou, F.F.; Nangaku, M.; Sharma, K.; Heerspink, H.J.L.; Garcia-Hernandez, A.; et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): A randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018, 6, 925–933. [CrossRef]
45. Nguyen, Q.D.; Sepah, Y.J.; Berger, B.; Brown, D.; Do, D.V.; Garcia-Hernandez, A.; Patel, S.; Rahhal, F.M.; Shildkrot, Y.; Renfurm, R.W. Primary outcomes of the VID1 study: Phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. *Int. J. Retin. Vitr.* **2019**, *5*, 1–14. [CrossRef] [PubMed]

46. Pharmaxis Ltd. Boehringer Ingelheim Discontinues Development of BI 1467335 for NASH. Available online: https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-discontinues-development-bi-1467335-nash (accessed on 20 January 2020).

47. Aeddula, N.; Pathireddy, S.; Ansari, A.; Juran, P. Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. *BMJ Case Rep.* **2018**. [CrossRef]

48. Novartis Products on NDA 008303. Available online: https://www.accessdata.fda.gov/scripts/cder/def/index.cfm?event=overview.process&ApplNo=008303 (accessed on 20 January 2020).

49. Énzsöly, A.; Markó, K.; Tábi, T.; Szökő, É.; Zelkó, R.; Tóth, M.; Petrasch, J.; Mátyus, P.; Németh, J. Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model. *J. Neural Transm.* **2013**, *120*, 969–975. [CrossRef]

50. Yang, W.; Li, H.; Luo, H.; Luo, W. Inhibition of semicarbazide-sensitive amine oxidase attenuates myocardial ischemia-reperfusion injury in an in vivo rat model. *Life Sci.* **2011**, *88*, 302–306. [CrossRef]

51. Wang, E.Y.; Gao, H.; Salter-Cid, L.; Zhang, J.; Huang, L.; Podar, E.M.; Miller, A.; Zhao, J.; O’Rourke, A.; Linnik, M.D. Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. *J. Med. Chem.* **2006**, *49*, 2166–2173. [CrossRef]

52. O’Rourke, A.; Wang, E.; Salter-Cid, L.; Huang, L.; Miller, A.; Podar, E.; Gao, H.; Jones, D.; Linnik, M. Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. *J. Neuroinflamm.* **2017**, *14*, 845–849. [CrossRef]

53. Salter-Cid, L.; Wang, E.; O’Rourke, A.; Miller, A.; Gao, H.; Huang, L.; Garcia, A.; Linnik, M. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. *J. Pharm. Exp.* **2005**, *315*, 553–562. [CrossRef]

54. Foot, J.S.; Deodhar, M.; Turner, C.I.; Yin, P.; Van Dam, E.M.; Silva, D.G.; Olivieri, A.; Holt, A.; McDonald, I.A. The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1). *Bioorg. Med. Chem. Lett.* **2012**, *22*, 3935–3940. [CrossRef]

55. Schilter, H.; Collison, A.; Russo, R.; Foot, J.; Yow, T.; Vieira, A.; Tavares, L.; Mattes, J.; Teixeira, M.; Jarolimek, W. Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. *Respir. Res.* **2015**, *16*, 42. [CrossRef] [PubMed]

56. Jarnicki, A.; Schilter, H.; Liu, G.; Wheeldon, K.; Essilfie, A.; Foot, J.; Yow, T.; Jarolimek, W.; Hansbro, P. The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model. *Br. J. Pharm.* **2016**, *173*, 3161–3175. [CrossRef] [PubMed]

57. Katagiri, D.; Hamaaki, Y.; Doi, K.; Negishi, K.; Sugaya, T.; Nangaku, M.; Noiri, E. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. *Kidney Int.* **2016**, *89*, 374–385. [CrossRef] [PubMed]

58. Foot, J.S.; Yow, T.T.; Schilter, H.; Buson, A.; Deodhar, M.; Findlay, A.D.; Guo, L.; McDonald, I.A.; Turner, C.I.; Zhou, W.; et al. PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. *J. Pharm. Exp.* **2013**, *347*, 365–374. [CrossRef]

59. Becchi, S.; Buson, A.; Foot, J.; Jarolimek, W.; Balleine, B.W. Inhibition of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 reduces lipopolysaccharide-induced neuroinflammation. *Br. J. Pharm.* **2017**, *174*, 2302–2317. [CrossRef]

60. Elo, P.; Tadayon, S.; Liljenbäck, H.; Teuho, J.; Käkelä, M.; Koskensalo, K.; Saanavara, V.; Virta, J.; Veres, T.; Kiviniemi, A.; et al. Vascular adhesion protein-1 is actively involved in the development of inflammatory lesions in rat models of multiple sclerosis. *J. Neuroinflamm.* **2018**, *15*, 128. [CrossRef]

61. Ma, Q.; Manaenko, A.; Khatibi, N.; Chen, W.; Zhang, J.; Tang, J. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. *J. Cereb. Blood Flow Metab.* **2011**, *31*, 881–893. [CrossRef]

62. Silvola, J.M.U.; Virtanen, H.; Sittenen, R.; Hellberg, S.; Liljenbäck, H.; Metsälä, O.; Stähle, M.; Saanjoki, T.; Käkelä, M.; Hakovirta, H.; et al. Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques. *Sci. Rep.* **2016**, *6*, 1–10. [CrossRef]
Inoue, T.; Morita, M.; Tojo, T.; Yoshihara, K.; Nagashima, A.; Moritomo, A.; Ohkubo, M.; Miyake, H. Synthesis of a novel semicarbazide-sensitive amine oxidase inhibitor, TERN-201, reduces NAS and fibrosis in rodent models of non-alcoholic steatohepatitis. In Proceedings of The International Liver Congress 2019 Abstract Book, Vienna, Austria, 10–14 April 2019; pp. e534–e535.

Horváth, Á.; Menghis, A.; Botz, B.; Borbély, É.; Kemeny, Á.; Tékus, V.; Csepregi, J.; Mócsai, A.; Juhász, T.; Zákány, R.; et al. Analgesic and anti-inflammatory effects of the novel semicarbazide-sensitive amine-oxidase inhibitor SzV-1287 in chronic arthritis models of the mouse. Sci. Rep. 2017, 7, 39863. [CrossRef] [PubMed]

Horváth, H.; Tékus, V.; Bencze, N.; Szentes, N.; Scheibch, B.; Böleské, K.; Szoke, E.; Mócsai, A.; Tóth-Sarudy, E.; Mátyus, P.; et al. Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors. Pharm. Res. 2018, 131, 231–243. [CrossRef] [PubMed]

Payrits, M.; Saghy, E.; Mátyus, P.; Czompa, Z.; Helyes, Z.; Szoke, E. A novel 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime compound is a potent Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist. Neuroscience 2016, 324, 151–162. [CrossRef] [PubMed]

Tabí, T.; Szoko, E.; Mérey, A.; Tóth, V.; Mátyus, P.; Gyires, K. Study on SSAO enzyme activity and anti-inflammatory effect of SSAO inhibitors in animal model of inflammation. J. Neural Transm. 2013, 120, 963–967. [CrossRef] [PubMed]

Noda, K.; Miyahara, S.; Nakazawa, T.; Almulki, L.; Nakao, S.; Hisatomi, T.; She, H.; Thomas, K.; Garland, R.; Miller, J.; et al. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J. 2008, 22, 1094–1103. [CrossRef]

Noda, K.; She, H.; Nakazawa, T.; Hisatomi, T.; Nakao, S.; Almulki, L.; Zandi, S.; Miyahara, S.; Ito, Y.; Thomas, K.L.; et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J. 2008, 22, 2928–2935. [CrossRef] [PubMed]

Noda, K.; Nakao, S.; Zandi, S.; Engelstädt, V.; Mashima, Y.; Hafezi-Moghadam, A. Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp. Eye Res. 2009, 89, 774–781. [CrossRef]

Yoshikawa, N.; Noda, K.; Ozawa, Y.; Tsubota, K.; Mashima, Y.; Ishida, S. Blockade of vascular adhesion protein-1 attenuates choroidal neovascularization. Mol. Vis. 2012, 18, 593–600. [PubMed]

Marttila-Ichihara, F.; Smith, D.J.; Stolen, C.; Yegutkin, G.G.; Elima, K.; Mercier, N.; Kiviranta, R.; Pihlavisto, M.; Alaranta, S.; Pentikäinen, U.; et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum. 2006, 54, 2852–2862. [CrossRef]

McDonald, I.; Foot, J.; Yin, P.; Fleming, E.; Van Dam, E. Semicarbazide-sensitive amine oxidase and vascular adhesion protein-1: One protein being validated as a therapeutic target for inflammatory diseases. Annu. Rep. Med. Chem. 2007, 42, 229–243. [PubMed]

Dunkel, P.; Balogh, B.; Meleddu, R.; Maccioni, E.; Gyires, K.; Matysu, P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: A patent survey. Expert Opin. Ther. Pat. 2011, 21, 1453–1471. [CrossRef] [PubMed]

Palfreyman, M.G.; McDonald, I.A.; Bey, P.; Danzin, C.; Zreika, M.; Cremer, G. Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential. J. Neural Transm. Suppl. 1994, 41, 407–414. [PubMed]

Nurminen, E.M.; Pihlavisto, M.; Lázár, L.; Pentikäinen, U.; Fülop, P.; Pentikäinen, O.T. Novel hydrazine molecules as tools to understand the flexibility of vascular adhesion protein-1 ligand-binding site: Toward more selective inhibitors. J. Med. Chem. 2011, 54, 2143–2154. [CrossRef] [PubMed]

Inoue, T.; Morita, M.; Tojo, T.; Yoshihara, K.; Nagashima, A.; Moritomo, A.; Ohkubo, M.; Miyake, H. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg. Med. Chem. 2013, 21, 1219–1233. [CrossRef] [PubMed]
80. Inoue, T.; Morita, M.; Tojo, T.; Nagashima, A.; Moritomo, A.; Imai, K.; Miyake, H. Synthesis and SAR study of new thiazole derivatives as vascular protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: Part 2. Bioorg. Med. Chem. 2013, 21, 2478–2494. [CrossRef]

81. Inoue, T.; Morita, M.; Tojo, T.; Nagashima, A.; Moritomo, A.; Miyake, H. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorg. Med. Chem. 2013, 21, 3873–3881. [CrossRef]

82. Emanuela, B.; Minarini, A.; Tumiatti, V.; Milelli, A.; Lunelli, M.; Pegoraro, M.; Rizzoli, V.; Di Paolo, M.L. Synthetic polyamines as potential amine oxidase inhibitors: A preliminary study. Amino Acids 2012, 42, 913–928. [CrossRef]

83. Yamaki, S.; Suzuki, D.; Fujiyasu, J.; Neya, M.; Nagashima, A.; Kondo, M.; Akabane, T.; Kadono, K.; Moritomo, A.; Yoshihara, K. Synthesis and structure-activity relationships of glycineamide derivatives as novel Vascular Adhesion Protein-1 inhibitors. Bioorg. Med. Chem. 2017, 25, 187–201. [CrossRef]

84. Yamaki, S.; Koga, Y.; Nagashima, A.; Kondo, M.; Shimada, Y.; Kadono, K.; Moritomo, A.; Yoshihara, K. Synthesis and pharmacological evaluation of glycineamide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition. Bioorg. Med. Chem. 2017, 25, 4110–4122. [CrossRef]

85. Ernberg, K.; McGrath, A.P.; Peat, T.S.; Adams, T.E.; Xiao, X.; Pham, T.; Newman, J.; McDonald, I.A.; Collyer, C.A.; Guss, J.M. A new crystal form of human vascular adhesion protein 1. Acta Cryst. Sect. F Struct. Biol. Cryst. Commun. 2010, 66, 1572–1578. [CrossRef]

86. Xu, H.; Salter-Cid, L.; Linnik, M.; Wang, E.; Paisansathan, C.; Pelligrino, D. Vascular adhesion protein-1 plays an important role in posts ischemic inflammation and neuropathology in diabetic, estrogen-treated ovarietomized female rats subjected to transient forebrain ischemia. J. Pharm. Exp. 2006, 317, 19–29. [CrossRef] [PubMed]

87. Li, R.; Li, H.; Luo, H.; Lin, Z.; Jiang, Z.; Luo, W. SSAO inhibitors suppress hepatocellular tumor growth in mice. Cell Immunol. 2013, 283, 61–69. [CrossRef] [PubMed]

88. Bligt-Lindén, E.; Arunanachalam, R.; Parkash, V.; Salminen, T.A. Structural comparison of the active site channels in rodent and primate vascular adhesion protein-1. J. Neural Transm. 2013, 120, 947–950. [CrossRef]

89. Best, C. The disappearance of histamine from autolysing lung tissue. J. Physiol. 1929, 67, 256–263. [CrossRef] [PubMed]

90. Bieganski, T.; Kusche, J.; Lorenz, W.; Hesterberg, R.; Stahlknecht, C.; Feussner, K. Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. Biochim. Biophys. Acta 1993, 756, 196–203. [CrossRef]

91. Schweiberger, H.G. The origin of mammalian plasma amine oxidases. J. Neural Transm. 2007, 114, 757–762. [CrossRef]

92. Kovacova-Hanuskova, E.; Buday, T.; Gavliakova, S.; Plevkova, J. Histamine, histamine intoxication and intolerance. Allergol. Immunopathol. (Madr.) 2015, 43, 498–506. [CrossRef]

93. Schweiberger, H.G. Origins of plasma amine oxidases in different mammalian species. Inflamm. Res. 2006, 55, 57–58. [CrossRef]

94. Honzawa, Y.; Nakase, H.; Matsuura, M.; Chiba, T. Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability. Inflamm. Bowel Dis. 2011, 17, E23–E25. [CrossRef]

95. Rosell-Camps, A.; Zibetti, S.; Pérez-Esteban, G.; Vila-Vidal, M.; Ferrés-Ramis, L.; García-Teresa-Garcia, E. Histamine intolerance as a cause of chronic digestive complaints in pediatric patients. Rev. Esp. Enferm. Dig. 2013, 105, 201–206. [CrossRef]

96. Maintz, L.; Benfadal, S.; Allam, J.-P.; Hagemann, T.; Fimmers, R.; Novak, N. Evidence for a reduced histamine degradation capacity in a subgroup of patients with atopic eczema. J. Allergy Clin. Immunol. 2006, 117, 1106–1112. [CrossRef] [PubMed]

97. Wagner, N.; Peveling-Oberhag, A.; Reese, I.; Rady-Pizarro, U.; Mitzel, H.; Staubach, P. A popular Myth—low-histamine diet improves chronic spontaneous urticaria—Fact or fiction? J. Eur. Acad. Derm. Venereol. 2016, 31, 650–655. [CrossRef] [PubMed]

98. Izquierdo-Casas, J.; Comas-Basté, O.; Latorre-Moratalla, M.; Lorente-Gascón, M.; Dueño, A.; Vidal-Carou, M.; Soler-Singla, L. Low Serum Diamine Oxidase (DAO) activity levels in patients with migraine. J. Physiol. Biochem. 2018, 74, 93–99. [CrossRef] [PubMed]
99. Anvari, S.; Vyhlidal, C.; Dai, H.; Jones, B. Genetic variation along the histamine pathway in children with allergic versus nonallergic asthma. *Am. J. Respir. Cell Mol. Biol.* 2015, 53, 802–809. [CrossRef] [PubMed]

100. Igaz, P.; Fitzimons, C.P.; Szalai, C.; Falus, A. Histamine genomics in silico: Polymorphisms of the human genes involved in the synthesis, action and degradation of histamine. *Am. J. Pharm.* 2002, 2, 67–72. [CrossRef]

101. Bytautiene, E.; Vedernikov, Y.P.; Saade, G.R.; Romero, R.; Garfield, R.E. Effect of histamine on phasic and tonic contractions of isolated uterine tissue from pregnant women. *Am. J. Obst. Gynecol.* 2003, 188, 774–778. [CrossRef]

102. Dale, H.; Laidlaw, P. The physiological action of β-iminazolylethylamine. *J. Physiol.* 1910, 41, 318–344. [CrossRef]

103. Gahl, W.; Raubertas, R.; Vale, A.; Golubjatnikov, R. Maternal serum diamine oxidase in fetal death and low-birth-weight infants. *Int. J. Obs. Gynaecol.* 1982, 89, 202–207. [CrossRef]

104. Myatt, L.; Roberts, J. Preeclampsia: Syndrome or disease? *Curr. Hypertens. Rep.* 2015, 17, 83. [CrossRef]

105. Velicky, P.; Windsperger, K.; Petroczi, K.; Pils, S.; Reiter, B.; Weiss, T.; Vondra, S.; Ristl, R.; Dekan, S.; Fiala, C.; et al. Pregnancy-associated diamine oxidase originates from extravillous trophoblasts and is decreased in early-onset preeclampsia. *Sci. Rep.* 2018, 8, 6342. [CrossRef]

106. Liang, X.; Zhao, Z.; Deng, W.; Tian, Z.; Lei, W.; Xu, X.; Zhang, X.; Su, R.; Yang, Z. Estrogen regulates amiloride-binding protein 1 through CCAAT/enhancer-binding protein-β in mouse uterus during embryo implantation and decidualization. *Endocrinology* 2010, 151, 5007–5016. [CrossRef] [PubMed]

107. Mezher, M. Regulatory Affairs Professionals Society. Available online: https://www.raps.org/regulatory-focusTM/news-articles/2015/4/who-makes-drug-side-effects-easier-to-find-with-new-database (accessed on 20 January 2020).

108. Chartier, M.; Morency, L.P.; Zylber, M.I.; Najmanovich, R.J. Large-scale detection of drug off-targets: Hypotheses for drug repurposing and understanding side-effects. *BMC Pharm. Toxicol.* 2017, 18, 18. [CrossRef] [PubMed]

109. Sjaastad, O. Potentiation by aminoguanidine of the sensitivity of sheep to histamine given by mouth. Effect of amino-guanidine on the urinary excretion of endogenous histamine. *Q. J. Exp. Physiol. Cogn. Med. Sci.* 1967, 52, 319–330. [PubMed]

110. EFSA Panel on Biological Hazards. 2011. Available online: https://www.efsa.europa.eu/en/panels/biohaz (accessed on 20 January 2020).

111. Kusche, J.; Izbicki, J.; Mennigen, R.; Curt, A.; Parkin, J. The effect of experimental carcinogenesis on intestinal diamine oxidase, a polyamine deaminating enzyme. *Cancer Detect. Prev.* 1986, 9, 17–29. [PubMed]

112. Sattler, J.; Lorenz, W. Intestinal diamine oxidases and enteral-induced histaminosis: Studies on three prognostic variables in an epidemiological model. *J. Neural Transm. Suppl.* 1990, 32, 291–314.

113. Yee, S.; Lin, L.; Mersk, M.; Keiser, M.; Gupta, A.; Zhang, Y.; Chien, H.; Shoichet, B.; Giacomini, K. Prediction and validation of enzyme and transporter off-targets for metformin. *J. Pharm. Pharm.* 2015, 42, 463–475. [CrossRef]

114. Brown, D.G.; Sanderson, M.R.; Garman, E.; Neidle, S. Crystal-structure of a berenil-d(CGCAAATTTGCG) complex: An example of drug DNA recognition based on sequence-dependent structural features. *J. Mol. Biol.* 1992, 226, 481–490. [CrossRef]

115. Edwards, K.J.; Jenkins, T.C.; Neidle, S. Crystal structure of a pentamidine-oligonucleotide complex: Implications for DNA-binding properties. *Biochemistry* 1992, 31, 7104–7109. [CrossRef]

116. Holt, A. Membrane-bound copper amine oxidases. In *Copper Amin Oxidases: Structures, Catalytic Mechanisms and Role in Pathophysiology*; Floris, G., Mondovi, B., Eds.; Taylor and Francis: Boca Raton, FL, USA, 2009; pp. 69–101.

117. Thornalley, P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. *Arch. Biochem. Biophys.* 2003, 419, 31–40. [CrossRef]

118. Abdel-Rahman, E.; Bolton, W.K. Pimagedine: A novel therapy for diabetic nephropathy. *Expert Opin. Investig. Drugs.* 2002, 11, 565–574.

119. Freedman, B.I.; Wuerth, J.P.; Cartwright, K.; Bain, R.P.; Dippe, S.; Hershon, K.; Mooradian, A.D.; Spinowitz, B.S. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). *Control. Clin. Trials* 1999, 20, 493–510. [CrossRef]
120. Kubota, R.; Reid, M.J.; Lieu, K.L.; Orme, M.; Diamond, C.; Tulberg, N.; Henry, S.H. Comparison of inhibitor and substrate selectivity between rodent and human vascular adhesion protein-1. *Mediat. Inflamm.* **2020**, *2020*, 3270513. [CrossRef]

121. Lyles, G.A. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: Biochemical, pharmacological and toxicological aspects. *Int. J. Biochem. Cell Biol.* **1996**, *28*, 259–274. [CrossRef]

122. Yu, P.H.; Zuo, D.M.; Davis, B.A. Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Species heterogeneity and stereoisomeric specificity. *Biochem. Pharm.* **1994**, *47*, 1055–1059. [CrossRef]

123. Marti, L.; Abella, A.; De La Cruz, X.; García-Vicente, S.; Unzeta, M.; Carpéné, C.; Palacín, M.; Testar, X.; Orozco, M.; Zorzano, A. Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: Identification of novel substrates with insulin-like activity. *J. Med. Chem.* **2004**, *47*, 4865–4874. [CrossRef] [PubMed]